Wells Fargo
ANAB icon

Wells Fargo’s AnaptysBio ANAB Stock Holding History

Wells Fargo’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82M Buy
41,707
+8,527
+26% +$517K ﹤0.01% 3327
2026
Q1 		$1.84M Buy
33,180
+10,973
+49% +$590K ﹤0.01% 3338
2025
Q4 		$1.08M Buy
22,207
+8,464
+62% +$330K ﹤0.01% 3910
2025
Q3 		$421K Sell
13,743
-19,585
-59% -$449K ﹤0.01% 4423
2025
Q2 		$740K Buy
33,328
+21,951
+193% +$459K ﹤0.01% 3882
2025
Q1 		$211K Buy
11,377
+257
+2% +$4.29K ﹤0.01% 4667
2024
Q4 		$147K Sell
11,120
-15,977
-59% -$387K ﹤0.01% 4975
2024
Q3 		$908K Buy
27,097
+533
+2% +$18.2K ﹤0.01% 3607
2024
Q2 		$666K Buy
26,564
+20,713
+354% +$482K ﹤0.01% 3732
2024
Q1 		$132K Buy
5,851
+830
+17% +$19.7K ﹤0.01% 4733
2023
Q4 		$108K Sell
5,021
-10,218
-67% -$176K ﹤0.01% 4852
2023
Q3 		$274K Sell
15,239
-8,191
-35% -$156K ﹤0.01% 4161
2023
Q2 		$477K Buy
23,430
+6,950
+42% +$141K ﹤0.01% 3981
2023
Q1 		$359K Buy
+16,480
New +$400K ﹤0.01% 4065
2022
Q4 		– Sell
-538
Closed -$13K – 7446
2022
Q3 		$13K Sell
538
-558
-51% -$13.1K ﹤0.01% 5564
2022
Q2 		$22K Sell
1,096
-19,694
-95% -$436K ﹤0.01% 5399
2022
Q1 		$514K Sell
20,790
-5,859
-22% -$177K ﹤0.01% 4383
2021
Q4 		$926K Sell
26,649
-37,335
-58% -$1.18M ﹤0.01% 4172
2021
Q3 		$1.74M Sell
63,984
-15,717
-20% -$399K ﹤0.01% 3785
2021
Q2 		$2.07M Buy
79,701
+20,077
+34% +$481K ﹤0.01% 3666
2021
Q1 		$1.28M Buy
59,624
+19,222
+48% +$485K ﹤0.01% 4071
2020
Q4 		$868K Buy
40,402
+25,206
+166% +$612K ﹤0.01% 4134
2020
Q3 		$224K Sell
15,196
-3,927
-21% -$70.8K ﹤0.01% 4903
2020
Q2 		$427K Buy
19,123
+4,346
+29% +$79.5K ﹤0.01% 4439
2020
Q1 		$209K Buy
14,777
+1,101
+8% +$16.7K ﹤0.01% 4655
2019
Q4 		$222K Sell
13,676
-21,477
-61% -$508K ﹤0.01% 4885
2019
Q3 		$1.23M Buy
35,153
+2,451
+7% +$117K ﹤0.01% 3684
2019
Q2 		$1.84M Sell
32,702
-247,868
-88% -$17.8M ﹤0.01% 3438
2019
Q1 		$20.5M Buy
280,570
+2,555
+0.9% +$176K 0.01% 1424
2018
Q4 		$17.7M Sell
278,015
-21,725
-7% -$1.62M 0.01% 1443
2018
Q3 		$29.9M Buy
299,740
+263,078
+718% +$21.8M 0.01% 1250
2018
Q2 		$2.6M Buy
36,662
+368
+1% +$30.9K ﹤0.01% 3251
2018
Q1 		$3.78M Buy
36,294
+12,701
+54% +$1.43M ﹤0.01% 2861
2017
Q4 		$2.38M Buy
23,593
+16,267
+222% +$1.2M ﹤0.01% 3230
2017
Q3 		$256K Buy
7,326
+3,516
+92% +$94.8K ﹤0.01% 4780
2017
Q2 		$91K Buy
3,810
+3,710
+3,710% +$93.2K ﹤0.01% 5204
2017
Q1 		$3K Buy
+100
New +$2.33K ﹤0.01% 6103

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Wells Fargo's ANAB Position: Q2 2026 in Review

Wells Fargo increased its AnaptysBio (ANAB) stake by 26% in Q2 2026, buying an estimated $517K and bringing the position to 41,707 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3327.

Wells Fargo first reported a position in ANAB in Q1 2017 and has held it in 37 quarters since. The position peaked at $29.9M in Q3 2018. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Wells Fargo held 41,707 shares of AnaptysBio worth $2.82M as of Q2 2026.
  • Wells Fargo bought 8,527 AnaptysBio shares in Q2 2026, an estimated $517K.
  • AnaptysBio made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3327 holding.
  • Wells Fargo first reported a position in AnaptysBio in Q1 2017 and has held it in 37 quarters since.
  • Wells Fargo's AnaptysBio position peaked at $29.9M in Q3 2018.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.